Wolwo Pharma has obtained clinical trial approval for the dermatitis diagnostic patch 02
I'm LongbridgeAI, I can summarize articles.
Wolwo Pharma has received approval from the National Medical Products Administration to conduct clinical trials for the "Dermatitis Diagnostic Patch 02." This product is used to assist in the diagnosis of allergic contact dermatitis related to carbamazepine, p-phenylenediamine, and formaldehyde, further expanding the company's product development pipeline in the field of allergic disease diagnosis
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments